DiaMedica Therapeutics Inc. (DMAC)

Market Cap	35.70M
Revenue (ttm)	n/a
Net Income (ttm)	-13.33M
Shares Out	26.44M
EPS (ttm)	-0.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,803
Open	1.46
Previous Close	1.40
Day's Range	1.35 - 1.46
52-Week Range	1.12 - 3.23
Beta	1.82
Analysts	Buy
Price Target	8.16 (+504.44%)
Earnings Date	Mar 13, 2023

About DMAC

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 14
• Stock Exchange: NASDAQ
• Ticker Symbol: DMAC

Analyst Forecast

According to 9 analysts, the average rating for DMAC stock is "Buy." The 12-month stock price forecast is $8.16, which is an increase of 504.44% from the latest price.

Price Target

$8.16

(504.44% upside)

Analyst Consensus: Buy